NCT07426406已完成不适用
A Study to Evaluate the Gastrointestinal Tolerance and Acceptability of a High Energy, High Protein, Oral Nutritional Supplement in Adults With or at Risk of Malnutrition
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 3
- 主要终点
- Gastrointestinal Tolerance
研究概览
简要总结
This is a multi-center, prospective, non-randomized, non-blinded, single-arm, single treatment study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has voluntarily signed and dated an ICF approved by an EC and provided applicable privacy authorization prior to any participation in the study.
- •Participant (male or female) is ≥ 18 years of age.
- •Participant is considered by a dietitian or clinician as malnourished or at risk for malnutrition based on current use of ONS, recently identified as malnourished or at risk of malnutrition based on a validated malnutrition screening tool, or has had weight loss within the last two months as a result of a hospitalization or a chronic illness.
- •Participant currently has normal GI function.
- •Participant requires ONS as assessed by a dietitian or clinician and is willing to comply with the study protocol for at least 7 days.
- •Non-pregnant, non-lactating female, at least 6 weeks postpartum prior to the screening visit. A urine pregnancy test is required for all female participants unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to the screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
- •If participant is of childbearing potential, the participant must agree to use effective forms of birth control methods for the duration of the study.
排除标准
- •Participant has severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.
- •Participant has a history of uncontrolled diabetes as evidenced by HbA1c of > 9% within the last six months.
- •Participant is currently taking or has taken antibiotics within 1 week prior to the feeding period (SDay 1 may be delayed until such time that the participant has completed a one-week washout period).
- •Participant has undergone major GI surgery less than 3 months prior to enrollment in the study.
- •Participant has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment.
- •Participant has an allergy or intolerance to any ingredient in the study nutritional product.
- •Participant has an aversion to all of the flavours of product being assessed.
- •Participant has an obstruction of the GI tract precluding ingestion or absorption of the study product, inflammatory bowel disease, gastric esophageal reflux disease, short bowel syndrome, or other major gastrointestinal disease-causing symptoms including (but not limited to) uncontrollable severe diarrhea, nausea, or vomiting. Exceptions include well-controlled reflux symptoms defined as no change in medication in the last 3 months.
- •Participant is currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect gastrointestinal motility. Exceptions include multivitamins/mineral supplements, optical steroids, and inhaled steroids for asthma.
- •Participation in another study that has not been approved as a concomitant study by Abbott.
- •Participant has a clinical condition that is contraindicated with this product as determined by the clinician in accordance with standard of care.
研究组 & 干预措施
Experimental Nutrition Product
Experimental
2 servings per day
干预措施: Experimental Nutrition Product (Other)
结局指标
主要结局
Gastrointestinal Tolerance
时间窗: Study Day 1 - Study Day 7
Bristol Stool Form Scale; Stool is classified into 7 groups (Types 1-7) with Type 3-4 as ideal stools
次要结局
- Nutritional Supplement Palatability(Study Day 1 - Study Day 7)
- Nutritional Supplement Compliance(Study Day 1 - Study Day 7)
研究者
研究点 (3)
Loading locations...
相似试验
尚未招募
不适用
Vegetarian Tube Feed StudyNCT07378111Société des Produits Nestlé (SPN)25
招募中
不适用
Acceptability and Tolerance Study of Bolus Tube Feed With Food BlendsNCT07341464Société des Produits Nestlé (SPN)50
招募中
1 期
Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers.Multiple Sclerosis2023-508439-30-00Neuraxpharm Pharmaceuticals S.L.210
已完成
不适用
Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for MalnutritionGastrointestinal ToleranceNCT04945083Abbott Nutrition25
招募中
不适用
Acceptability and Tolerance Study of a Plant-based Tube FeedNutrition DisordersNCT06209593Société des Produits Nestlé (SPN)15